Advicenne Announces Commercialization Agreement with FrostPharma AB for Sibnayal™ in the Nordic Region
04 Janvier 2022 - 7:00AM
Business Wire
- Advicenne will receive a transfer price and
royalties for an amount markedly higher than 50% of future sales of
Sibnayal™ - Sibnayal™ will be marketed to one-third of European
patients by three members of the exclusive ‘Your Pharma Partner’
network
Regulatory News:
Advicenne (Euronext: ADVIC) (or the "Company"),
a specialty pharmaceutical company dedicated to developing and
commercializing innovative treatments for those suffering from rare
renal diseases, is pleased to announce that it has signed an
exclusive distribution agreement with FrostPharma AB
(“FrostPharma”), a Swedish pharmaceutical company, for the
commercialization of Sibnayal™ in the Nordic region (Denmark,
Finland, Iceland, Norway, and Sweden).
The partnership with FrostPharma is the third Advicenne has
signed for Sibnayal™ in Europe, following the recently signed
similar collaborations with TwinPharma in Benelux, and ExCEEd
Orphan in Central and Eastern European Countries. The three
companies comprise the exclusive ‘Your Pharma Partner' network,
providing services and delivering innovative treatments to patients
in 25 European countries. With these three partners, Sibnayal™ will
be made available to about a third of European patients.
Sibnayal™ is the first and only label-approved drug for the
treatment of Distal renal tubular acidosis (dRTA) in adults,
adolescents, and children aged one year and older. Earlier this
year, the European Commission granted marketing authorisation to
Sibnayal™ for the treatment of dRTA.
Under the terms of the agreement, FrostPharma will receive
exclusive marketing rights to Sibnayal™ for the treatment of dRTA
in its respective market. For its part, Advicenne will receive a
transfer price for the sale of its product and royalties for an
amount significantly higher than 50% of future sales. As part from
the agreement, FrostPharma is also managing the Early Access
Program running for Sibnayal™ in Sweden.
Didier Laurens, Chief Executive Officer of Advicenne,
commented: “We are delighted to be partnering with FrostPharma,
a leader in the commercialization of a broad range of products
across many disease areas. This is Advicenne’s third partnership
for the commercialization of Sibnayal™ in just over a few weeks and
is testament of our Company’s momentum. We have found in
FrostPharma a partner that shares our same goal: delivering
life-changing treatments for patients in areas of huge unmet need
and we are looking forward to working together.”
Clas Lindbergson, Head of Business Development of FrostPharma
stated: “We are proud to be partnering with Advicenne for the
delivery of Sibnayal™ to patients and improve the lives of those
suffering from Distal Renal Tubular Acidosis (dRTA). We look
forward to working with them and to be continuing to expand our
product portfolio in areas of high unmet need.”
About Advicenne
Advicenne (Euronext: ADVIC) is a specialty pharmaceutical
company founded in 2007, specializing in the development of
innovative treatments in Nephrology. Its lead product SibnayalTM
(ADV 7103) has received its Marketing Approval for distal renal
tubular acidosis in EU and the UK. ADV 7103 is currently in
late-stage development in cystinuria in Europe and in dRTA and
cystinuria in the US. Headquartered in Paris, Advicenne has been
listed on the Euronext Paris stock exchange since 2017 and was
cross-listed on the Euronext Brussels stock exchange in 2019. For
additional information see: https://advicenne.com/.
About Frost Pharma AB
FrostPharma AB is an entrepreneurial Swedish pharmaceutical
company specialized in commercialization of products creating
value. Since the start in 2017, FrostPharma has successfully
commercialized a broad range of products across multiple disease
areas, covering all Nordic countries and beyond. Key to success is
the ability to match specific patient- and healthcare needs with
relevant products in relation to our extensive in-house
commercialization competence. www.frostpharma.se
About Your Pharma Partner in Europe
Your Pharma Partner in Europe is a joint collaboration alliance
between the independent pharmaceutical companies TwinPharma
(the Netherlands), FrostPharma (Sweden) and ExCEEd
Orphan (Central and Eastern Europe). One single point of
contact gives the opportunity to reach a combined market of 180
million Europeans in 25 countries. www.yourpharmapartner.eu
Forward-Looking Statements
This press release contains certain forward-looking statements
relating to the business of Advicenne, which shall not be
considered per se as historical facts. Such statements include
projections and estimates, and the hypotheses on which these are
based, as well as observations relating to operations, ongoing
projects, objectives, the development of products and their future
performance, and expectations regarding financial results.
In some cases, forward-looking statements can be identified by
words such as "could," "should," "may," "expects," "anticipates,"
"believes," "intends," "estimates," "aims," "targets" or similar
words. Although the management of Advicenne believes that these
forward-looking statements are reasonably made, investors should be
aware that they are subject to a number of known and unknown risks
and uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
these forward-looking statements. In particular, the expectations
of Advicenne could be affected by, among other things,
uncertainties involved in the placing on the market and
commercialization of Advicenne products or any other risks and
uncertainties developed or identified in any public documents filed
by Advicenne with the French Financial Markets Authority (Autorité
des marchés financiers (AMF)), including those listed in Chapter 3,
“Risk Factors,” of its universal registration document, filed with
the latter on December 6, 2021. Notwithstanding the compliance with
article 223-1 of the General Regulation of the AMF (the information
disclosed must be “accurate, precise and fairly presented”),
Advicenne disclaims any intention or obligation to publicly update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220103005399/en/
Advicenne Didier Laurens, CEO +33 (0)4 66 05 54 20 Email:
investors@advicenne.com Consilium Strategic Communications
Mary-Jane Elliott, Ashley Tapp, Davide Salvi +44 (0)20 3709 5700
Email: advicenne@consilium-comms.com
Ulysse Communication Media relations Bruno Arabian +33
(0)6 87 88 47 26 Email: advicenne@ulysse-communication.com